EuroBiotech: More Articles of Note

Newspapers

> HaYa Therapeutics and GNUbiotics became the first companies to join the Swiss Biopole startup incubator. The startups will move into the facility when it opens in the spring of 2018, becoming the first of the 10 to 12 companies Biopole expects to host at any one time. Statement (PDF)

> Carrick Therapeutics dosed the first patient in a phase 1 trial of its cyclin-dependent Kinase 7 selective inhibitor. The cancer candidate is expected to move into an efficacy trial next year. Release

> Gene therapy startup Orchard Therapeutics expanded its technical operations in California. The expansion quadruples the U.K. biotech’s technical operations laboratory footprint. Statement 

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> Symphogen pocketed a $5 million (€4 million) milestone after Roche’s Genentech moved a Staphylococcus aureus candidate into phase 1b. Release

> Analysts talked up the prospect of Johnson & Johnson buying Genmab. Reuters